3.32 USD
-0.1 (-2.92%)
3.35 USD
+0.03 (+0.9%)
ChartMill assigns a Buy % Consensus number of 74% to RCKT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.03. This target is 141.94% above the current price.
RCKT was analyzed by 21 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about RCKT.
In the previous month the buy percentage consensus was at a similar level.
RCKT was analyzed by 21 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-18 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2025-11-18 | B of A Securities | Maintains | Buy -> Buy |
| 2025-10-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-10-03 | Leerink Partners | Maintains | Market Perform -> Market Perform |
| 2025-08-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-20 | B of A Securities | Upgrade | Neutral -> Buy |
| 2025-08-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-07-25 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-07-25 | B of A Securities | Downgrade | Buy -> Neutral |
| 2025-07-24 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-24 | Needham | Maintains | Hold -> Hold |
| 2025-06-17 | UBS | Maintains | Buy -> Buy |
| 2025-06-03 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-28 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-05-28 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-28 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-05-28 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-05-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-05-28 | Jefferies | Downgrade | Buy -> Hold |
| 2025-05-27 | Needham | Downgrade | Buy -> Hold |
| 2025-05-16 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-05-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-05-12 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-05-12 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-05-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-04-09 | Needham | Reiterate | Buy -> Buy |
ROCKET PHARMACEUTICALS INC / RCKT FAQ
What is the price target for RCKT stock?
21 analysts have analysed RCKT and the average price target is 8.03 USD. This implies a price increase of 141.94% is expected in the next year compared to the current price of 3.32.
What is the consensus rating for ROCKET PHARMACEUTICALS INC (RCKT) stock?
The consensus rating for ROCKET PHARMACEUTICALS INC (RCKT) is 74.2857 / 100 . This indicates that analysts generally have a positive outlook on the stock.